Evidence map›Paper›PMID 36856851›Full record

SynthesisJournal of cancer research and clinical oncology2023

Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis.

Maoyang Dou, Hao Liang, Yang Liu, Qiujie Zhang, Ruowen Li, Shouzhen Chen, Benkang Shi

Open access · greenAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Maoyang DouDepartment of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong Province, China.
Hao LiangDepartment of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong Province, China.
Yang LiuDepartment of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong Province, China.
Qiujie ZhangDepartment of Health Care, Qilu Hospital of Shandong University, Jinan City, Shandong Province, China.
Ruowen LiDepartment of Hernia and Abdominal Wall Surgery, Qilu Hospital of Shandong University, Jinan City, Shandong Province, China.
Shouzhen Chen *Department of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong Province, China. chenshouzhen1990@163.com.
Benkang Shi *Department of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong Province, China. bkang68@sdu.edu.cn.
Qilu Hospital of Shandong University · CNWeifang Medical University · CN

Funding

National Natural Science Foundation of China 81800672National Natural Science Foundation of China 81900637Primary Research & Development Plan of Shandong Province 2019GSF108123Taishan Scholar Foundation of Shandong Province ts201511092
6 · The paper itself

Abstract

purposeThe newly published ARASENS trial has demonstrated the clinical efficacy of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC). However, the use of darolutamide as the latest first-line androgen receptor pathway inhibitor for mHSPC has not been compared with other androgen receptor targeted agents (ARTAs). Given the lack of head-to-head randomized trials, we performed this updated meta-analysis to conduct indirect comparison for the efficacy and safety of darolutamide with other new-generation ARTAs.

methodsBy searching the databases of PubMed, Scopus, Cochrane Library, and Embase, 9 large randomized controlled trials evaluating ARTAs for mHSPC patients were eventually screened according to PRISMA. We extracted data from overall survival, castration-resistant progression, and adverse events for network meta-analysis using the Bayesian and standard frequentist models.

resultsDarolutamide combination emerged with superiority (HR = 0.68, 95%CrI = 0.57-0.81) among four androgen receptor inhibitors for patients with high Gleason score (HR = 0.71, 95%CrI = 0.59-0.86). Darolutamide was best tolerated in several androgen suppression-related adverse events (AEs).

conclusionDarolutamide appears to be an optional androgen receptor inhibitor for mHSPC patients, especially for patients with Gleason score ≥ 8. Its well-tolerated characteristic may provide a preferred drug option for patients with poor cardiovascular function and bone health.

Indexed as

Prostatic Neoplasms, Castration-ResistantReceptors, AndrogenAndrogen AntagonistsAndrogen Receptor AntagonistsBayes TheoremHormonesHumansMalePyrazolesRandomized Controlled Trials as TopicAndrogen AntagonistsAndrogen Receptor AntagonistsdarolutamideHormonesPyrazolesReceptors, AndrogenAndrogen receptor targeted agentsAndrogen suppressionDarolutamidemHSPCNetwork meta-analysis

Identifiers

PMID36856851
PMCPMC11798062
OpenAlexW4322719476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.